echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Shiyao exerts strength, 14 new class 1 drugs are coming intensively this year

    Shiyao exerts strength, 14 new class 1 drugs are coming intensively this year

    • Last Update: 2021-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On October 26, CSPC Zhongqi Pharmaceutical's clinical application for SYHX2001 tablets submitted as a new drug category 1 was accepted by the CDE, and the product was declared for clinical use in China for the first time
    .


    According to data from Meinenet, since 2021, CSPC has submitted clinical applications for 14 Class 1 new drugs, and many have been approved for clinical use


    Source: CDE official website

    On October 26, the first class 1 new drug SYHX2001 tablet of CSPC Zhongqi Pharmaceutical was applied for clinical application for the first time
    .


    In addition to this product, CSPC (including subsidiaries, the same below) this month has 4 new drugs for clinical application, including Class 1 new drug recombinant anti-PD-1 fully human monoclonal antibody injection (not the first time), Class 2.


    As a traditional Big Pharma in China, CSPC adheres to an innovative R&D strategy, increasing R&D investment year by year, and steadily advancing the product line under research
    .


    According to data from Minai.


    Duensibu was approved by the FDA in September 2018.


    From 2021 to the present, CSPC has applied for clinical Class 1 new drugs

    Source: Meinenet MED2.


    14 new class 1 drugs are concentrated in the field of anti-tumor therapy, including SYHA1402 tablets, recombinant fully human anti-RANKL monoclonal antibody injection, TG103 injection, recombinant anti-PD-1 fully human monoclonal antibody injection and other non-first clinical applications


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.